PMC7105942_01
Clinical images of Case 1. (A1) Brain MRI with contrast of brain for patient 1 displaying normal status before EGFR-TKI therapy; (A2) Brain MRI showed increased ischemic foci and lacunar infarction, serious encephalatrophy, and demyelination after EGFR-TKI therapy; (B) Chest CT with contrast of patient 1 showed gradually decreasing pleural effusion in EGFR-TKI treatment.
EXCLI-19-230-g-001.jpg
PMC7105942_01_EXCLI-19-230-g-001.jpg
F1
A 44-year-old male (Figure 1(Fig. 1)) initially presented with cough and expectoration repeatedly in March 2016.
PMC7105942_02
Clinical images of Case 2. (A1) Brain MRI with contrast showed suspicious reinforcement in the epencephalon and some ischemic areas in the frontal, parietal, and occipital lobes before EGFR-TKI therapy; (A2) Brain MRI showed multiple ischemic foci and lacunar infarction, encephalatrophy, and demyelination in white matter after EGFR-TKI therapy; (B) Chest CT with contrast of patient 2 showed partial response in chest lesions after EGFR-TKI treatment.
EXCLI-19-230-g-002.jpg
PMC7105942_02_EXCLI-19-230-g-002.jpg
F2
A 62-year-old female (Figure 2(Fig. 2)) initially presented with low back pain in
PMC7105942_03
PMC7105942_04
Clinical images of Case 4. (A1) Brain MRI showed some ischemic foci in the frontal lobe and slight demyelination before EGFR-TKI therapy; (A2) Brain MRI showed more ischemic foci in the frontal lobe, bilateral ventricle and basal ganglia region, lacunar infarction, demyelination, and encephalatrophy after EGFR-TKI therapy; (B) Chest CT with contrast of patient 4 showed partial response in chest lesions after EGFR-TKI treatment.
EXCLI-19-230-g-003.jpg
PMC7105942_04_EXCLI-19-230-g-003.jpg
F3
The patient was a 66-year-old female (Figure 3(Fig. 3)) who had a pre-existing depressive disorder and took Duloxetine regularly.
PMC7105942_05
Clinical images of Case 5. (A1) Brain MRI showed multiple nodules in the brain, and metastatic tumor was considered; (A2) Brain MRI showed more ischemic foci and lacunar infarction in the bilateral frontal and parietal lobes and demyelination after 3 months of EGFR-TKI therapy; (A3) Brain MRI showed shrinking metastatic tumor in the brain, more and more ischemic foci and lacunar infarction in the bilateral frontal and parietal lobes, and demyelination after 6 months of EGFR-TKI therapy; (B) Chest CT with contrast of patient 5 showed the gradual disappearance of pulmonary nodules after EGFR-TKI treatment.
EXCLI-19-230-g-004.jpg
PMC7105942_05_EXCLI-19-230-g-004.jpg
F4
A 63-year-old male (Figure 4(Fig. 4)) initially presented with cough and sputum and was diagnosed with lung cancer.